Professional Documents
Culture Documents
DOI 10.1007/s10337-010-1832-2
ORIGINAL
Received: 8 July 2010 / Revised: 22 September 2010 / Accepted: 19 October 2010 / Published online: 8 January 2011
Ó The Author(s) 2011. This article is published with open access at Springerlink.com
123
68 I. V. Kudris et al.
123
Analysis of Amisulpride in Human Plasma by SPE and LC 69
corresponding calibration standard and the procedure for emission wavelengths 274 and 370 nm, respectively) was
sample preparation, described below, was carried out. used for detection of amisulpride and the IS.
To prepare quality-control samples 250 lL of the
appropriate amisulpride working solution was diluted with Optimization of SPE
25 mL human plasma to furnish concentrations of 30, 300,
and 900 ng mL-1. Solid-phase extraction (SPE) was chosen for sample prep-
To prepare amisulpride samples with concentrations aration. This method enables simultaneous and rapid pro-
above the calibration range (1,800 ng mL-1), 500 lL cessing of many samples, cleaning extracts from biological
amisulpride working solution (concentration 90 lg mL-1) material and concentration of determined compounds.
was diluted with 25 mL human plasma. This solution was Oasis HLB cartridges were chosen for extraction of
used to test the integrity of the dilution procedure. amisulpride and the internal standard from plasma samples.
IS solution (100 lg mL-1, 15 lL) was added to 1.5 mL These cartridges contain adsorbent with both hydrophobic
of the corresponding validation sample and the procedure and hydrophilic properties. Preliminary sample extraction
for sample preparation, described below, was carried out. conditions were selected by using aqueous solutions the
compounds investigated. The amisulpride and IS content of
Sample Preparation washings from the cartridge were determined after each
stage of sample preparation (sorption, washing, and col-
Frozen plasma samples were thawed at ambient tempera- lection). Sample-preparation conditions were the same as
ture (20 ± 2 °C) and vortex-mixed for 30 s. Plasma those proposed by the cartridge manufacturer: conditioning
(1.5 mL) was placed in a plastic tube, 15 lL IS solution (pre-washing) with 1 mL methanol then 1 mL water,
(100 lg mL-1) was added, and vortex mixing was per- washing with water and 30% (v/v) methanol–water, then
formed for 30 s. Samples were centrifuged at 11,000g for collection by use of 1 mL methanol. Amisulpride and the IS
15 min. After centrifugation, 1.0 mL of the supernatant were not found in the washing liquids after the adsorption
was loaded on to a previously activated SPE cartridge. The and washing stages. The methanolic sample solution
cartridge was washed with 1 mL pure water then the obtained in the collection stage was dried under vacuum and
amisulpride and metoclopramide were eluted with 1.0 mL the residue was re-dissolved in 1.0 mL water–acetonitrile
methanol. The eluent was collected in a polypropylene tube 75:25 (v/v). The amisulpride and IS content were approxi-
and evaporated to dryness under vacuum at 58 °C. The mately 90 and 80%, respectively, of the theoretical values
residue was reconstituted with 500 lL water–acetonitrile (determined by analysis of solutions containing the com-
mixture 75:25 (v/v) and the solution was vortex-mixed and pounds without the sample-preparation stage).
analyzed. After development, sample extraction was performed on
plasma containing known concentrations of analyte and IS.
Instrumentation and Chromatographic Conditions Endogenous plasma components did not interfere with the
compounds of interest after their isolation by use of SPE.
HPLC was performed with a Perkin Elmer (Shelton, USA) Pure acetonitrile, a mixture of equal volumes of acetonitrile
series 200 system consisting of vacuum degasser, gradient and methanol, and double the volume of methanol were
pump, thermostatic autosampler, column oven, fluores- used as liquids for collection of amisulpride and IS but,
cence detector, diode-array detector, and network chro- because these solvents did not lead to more efficient
matographic interface (NCI 900). TotalChrom ver. 6.0 extraction, 1 mL methanol was chosen for collection.
software (Perkin Elmer) was used for acquisition and
processing of chromatographic data. Optimization of LC
Chromatographic separation was performed at 35 °C on
a 250 9 4.6 mm i.d., particle size 5 lm, Zorbax SB-CN High-performance liquid chromatography with different
analytical column (Agilent Technologies, USA) with a methods of detection have been used for pharmacokinetic
12.5 9 4.6 mm i.d., particle size 5 lm, Zorbax SB-CN studies of amisulpride. We compared the sensitivity for
guard column (Agilent). The mobile phase was 0.03 M amisulpride using the same chromatographic conditions
phosphate buffer (pH 6.5)–acetonitrile 65:35 (v/v). The but with application of diode-array and fluorescence
0.03 M phosphate buffer solution (pH 6.5) was prepared by detection. The DAD was set at the wavelength of maxi-
dissolving 4.1 g potassium dihydrogen phosphate in mum absorption, 274 nm, and fluorescence detection was
950 mL pure water, adjusting to pH 6.5 ± 0.1 with tri- performed with excitation and emission wavelengths of
ethylamine, and diluting to 1,000 mL with pure water. The 274 and 370 nm, respectively. It was established that under
mobile phase flow-rate was 1 mL min-1 and the injection similar chromatographic conditions fluorescence detection
volume was 40 lL. Fluorescence detection (excitation and was six times more sensitive that UV detection.
123
70 I. V. Kudris et al.
123
Analysis of Amisulpride in Human Plasma by SPE and LC 71
Fig. 2 Chromatograms
obtained from a Blank human
plasma; b Plasma spiked at the
LLOQ (10 ng mL-1
amisulpride and 1,000 ng mL-1
metoclopramide (IS)); c Plasma
spiked at the ULOQ
(1,000 ng mL-1 amisulpride
and 1,000 ng mL-1
metoclopramide)
20% and accuracy between 80 and 120%. The average Intra-day and inter-day accuracy and precision were
LLOQ from five determinations was 10 ng mL-1. evaluated by analysis of quality-control samples contain-
ing amisulpride at three different concentrations—a low
Accuracy and Precision concentration (LQC), 30 ng mL-1, a concentration near
the centre of the calibration plot (MQC), 300 ng mL-1,
Accuracy and precision were determined by replicate anal- and a concentration near the upper limit of the calibration
ysis of samples with known amisulpride content. The mean plot (HQC), 900 ng mL-1. Intra-day accuracy and preci-
value should be within 15% of the actual value [16, 20, 21]. sion were evaluated by analysis of these QC samples
The difference between mean amounts of amisulpride added prepared and analyzed on 1 day (eight samples of each
and recovered (RE, %) serves as a measure of accuracy. The concentration; three replicate injections). Inter-day accu-
coefficient of variation (CV, %), as a measure of precision at racy and precision were evaluated by analysis of these
each concentration, should not exceed 15%. QC samples prepared and analyzed on five different days
123
72 I. V. Kudris et al.
123
Analysis of Amisulpride in Human Plasma by SPE and LC 73
LQC level
Short-term 27.8 ± 0.4 -7.26 1.59 28.5 ± 1.1 -5.00 3.96 -2.38
Freeze–thaw 27.7 ± 1.1 -7.65 3.84 28.5 ± 1.1 -5.00 3.96 -2.79
Post preparative 29.10 ± 0.42 -3.01 1.43 28.5 ± 1.1 -5.00 3.96 2.09
Long-term 30.4 ± 0.8 1.35 2.66 31.3 ± 0.6 4.25 2.01 -2.78
HQC level
Short-term 829 ± 33 -7.92 3.95 836 ± 10 -7.14 1.18 -0.85
Freeze–thaw 845 ± 11 -6.15 1.29 837 ± 10 -7.14 1.18 1.06
Post preparative 852 ± 12 -5.38 1.31 836 ± 10 -7.14 1.18 1.89
Long-term 947 ± 22 5.19 2.31 972 ± 7 8.00 0.70 -2.60
123
74 I. V. Kudris et al.
A paired t test was used for statistical evaluation of the data 2. Costa JA, Silva E (1990) Ann Psychiatr 5:242–256
and all statistical calculations were defined at the level 3. Agnoli A, Ravizza L, Torta R (1989) In: Proc 37th Italian
Psychiatry Society Congress, Rome, 6–11 February 1989, CIC
P B 0.05. Typical pharmacokinetic profiles (plasma con- International, Rome
centration–time) for the two amisulpride preparations are 4. Josserand F, Weber F (1988) Ann Psychiatr 3:306–312
presented in Fig. 3 and the main pharmacokinetic data are 5. Noble S, Benfield P (1999) CNS Drugs 12:471–477
summarized in Table 5. 6. Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk
I, Ahtoy P, Chretien P, Rosenzweig P, Nasr A, Piette F (1998)
Eur J Clin Pharmacol 54:405–415
7. Kamizono A, Inotsume N, Miyamote K, Ueda K, Miyakawa T,
Conclusion Arimoto H, Nakano M (1991) J Chromatogr B 567:113–119
8. Mokrim R, Brunet C, Cazin M, Gressier B, Luyckx M, Dine T,
Robert H, Cazin JC (1993) Methods Find Exp Clin Pharmacol
A simple, accurate, rapid, and selective reversed-phase LC 15:41–50
method with fluorescence detection for analysis of ami- 9. Frahnert C, Rao ML, Grasmäder K (2003) J Chromatogr B
sulpride in human plasma after its isolation by solid-phase 794:35–40. doi:10.1016/S1570-0232(03)00393-3)
extraction has been developed and validated. A one-step 10. Sachse J, Härtter S, Weigmann H, Hiemke C (2003) J Chroma-
togr B 784:405–411. doi:10.1016/S1570-0232(02)00808-5
solid-phase extraction procedure is proposed for prepara- 11. Pehourcq F, Ouariki S, Begaud B (2003) J Chromatogr B
tion of plasma samples for analysis of amisulpride during 789:101–117. doi:10.1016/S1570-0232(03)00045-X
pharmacokinetic investigations. 12. Kirchherr H, Kühn-Velten WN (2006) J Chromatogr B
The sensitivity of the method (LLOD) was almost the 843:100–105. doi:10.1016/j.jchromb.2006.05.031
13. Gschwend MH, Arnold P, Ring J, Martin W (2006) J Chromatogr
same as that described in the literature for analogous phar- B 831:132–140. doi:10.1016/j.jchromb.2005.11.042
macokinetic studies, but in this method the amisulpride 14. Malavasi B, Locatell M, Ripamonti M, Ascalone V (1996)
ULOQ was increased substantially—up to 1,000 ng mL-1— J Chromatogr B 676:107–112
because the orally administered dose was increased to 15. Ascalone V, Ripamonti M, Malavasi B (1996) J Chromatogr B
676:95–101
200 mg compared with 50 mg investigated previously, and 16. Guidance for industry, bioanalytical method validation. US
because of the need to perform pharmacokinetic investiga- Department of Heaths and Human Services, Food and Drug
tions with this pharmaceutical preparation (Soleron 200). Administration, Center for Drug Evaluation and Research
The method was successfully applied to a bioequiva- (CDER), Rockville, MD, 2001. http://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm064
lence study of two amisulpride preparations after oral 964.htm
administration of a 200-mg dose to eighteen healthy vol- 17. United States Pharmacopoeia 32/National Formulary 27 (2009)
unteers. It was demonstrated that both amisulpride prepa- United State Pharmacopoeial Convention. Rockville, MD,
rations had similar pharmacokinetic properties. pp 733–740
18. International Conference of Harmonization, Q2A: Text on vali-
dation of analytical procedures. (1995) US FDA Federal Register,
Acknowledgments This work was supported by Pharma Start Ltd, V. 60, March, pp 11260–11273
(Kyiv, Ukraine), sponsor of the bioequivalence study of two ami- 19. International Conference of Harmonization, Q2B: Validation of
sulpride preparations (Solian 200 mg, Sanofi Winthrop Industrie S.A., analytical procedures: methodology. (1997) US FDA Federal
Gentille, France and Soleron 200, Pharma Start, Kyiv, Ukraine). Register, V. 62, May, pp 27463–27495
20. Bansal S, DeStefano A (2007) AAPS J 9:109–115. doi:10.1208/
Open Access This article is distributed under the terms of the aapsj0901011
Creative Commons Attribution Noncommercial License which per- 21. Viswanathan C, Bansal S, Booth B, DeStefano A, Rose M,
mits any noncommercial use, distribution, and reproduction in any Sailstad J, Shah V, Skelly J, Swann P, Weiner R (2007) AAPS J
medium, provided the original author(s) and source are credited. 9:30–38. www.aapsj.org (doi:10.1208/aapsj0901004)
22. Nowatzke W, Woolf E (2007) AAPS J 9:117–122. doi:10.1208/
aapsj0902013
References
123